Phase II evaluation of E7389 (NSC-707389) [eribulin] in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2015
At a glance
- Drugs Eribulin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 16 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is now 1 Dec 2007.
- 20 Dec 2007 Status changed from recruiting to in progress.